分组1 - Viking Holdings reported quarterly earnings of $0.99 per share, matching the Zacks Consensus Estimate, and up from $0.76 per share a year ago [1] - The company posted revenues of $1.88 billion for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 2.59%, compared to $1.59 billion in the same quarter last year [2] - Viking shares have increased approximately 36.6% year-to-date, outperforming the S&P 500's gain of 9.7% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $1.18 on revenues of $2 billion, and for the current fiscal year, it is $2.49 on revenues of $6.36 billion [7] - The Leisure and Recreation Services industry, to which Viking belongs, is currently ranked in the bottom 27% of over 250 Zacks industries, indicating potential challenges ahead [8]

Group 1 - Medtronic reported quarterly earnings of $1.26 per share, exceeding the Zacks Consensus Estimate of $1.23 per share, and showing an increase from $1.23 per share a year ago, resulting in an earnings surprise of +2.44% [1] - The company achieved revenues of $8.58 billion for the quarter ended July 2025, surpassing the Zacks Consensus Estimate by 2.50%, and up from $7.92 billion year-over-year [2] - Medtronic has outperformed the S&P 500 with a share price increase of about 16.2% since the beginning of the year, compared to the S&P 500's gain of 9.7% [3] Group 2 - The current consensus EPS estimate for the upcoming quarter is $1.33 on revenues of $8.73 billion, and for the current fiscal year, it is $5.55 on revenues of $35.29 billion [7] - The Zacks Industry Rank indicates that the Medical - Products industry is in the top 39% of over 250 Zacks industries, suggesting that stocks in the top 50% outperform those in the bottom 50% by more than 2 to 1 [8]

Core Viewpoint - JELD-WEN shows a significant improvement in earnings outlook, making it an attractive investment option as analysts continue to raise earnings estimates for the company [1][3]. Earnings Estimate Revisions - The rising trend in earnings estimate revisions reflects growing analyst optimism about JELD-WEN's earnings prospects, which is expected to positively impact its stock price [2]. - For the current quarter, JELD-WEN is projected to earn $0.25 per share, a decrease of 21.9% from the previous year, but the Zacks Consensus Estimate has increased by 8.57% over the last 30 days due to one upward revision [6]. - For the full year, the earnings estimate stands at $0.27 per share, representing a decline of 65.4% from the prior year, yet the trend remains encouraging with one upward revision and no negative revisions [7]. Zacks Rank and Performance - JELD-WEN has achieved a Zacks Rank 2 (Buy), indicating strong potential for outperformance based on favorable estimate revisions [8]. - Stocks with Zacks Rank 1 (Strong Buy) and 2 (Buy) have historically outperformed the S&P 500, suggesting a positive outlook for JELD-WEN [8]. Stock Performance - The stock has gained 37.6% over the past four weeks, driven by solid estimate revisions, indicating strong earnings growth prospects that may further elevate the stock price [9].

Shares of Mineralys Therapeutics, Inc. (MLYS) have gained 2% over the past four weeks to close the last trading session at $14.52, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $36.25 indicates a potential upside of 149.7%. The average comprises eight short-term price targets ranging from a low of $15.00 to a high of $48.00, with a standard deviation of $11.25. While the lowes ...

Core Insights - Zevra Therapeutics reported a quarterly earnings of $1.21 per share, which was below the Zacks Consensus Estimate of $2.19, resulting in an earnings surprise of -44.75% [1] - The company posted revenues of $25.88 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 14.35%, and showing significant growth from $4.45 million in the same quarter last year [2] - The stock has increased approximately 40.3% year-to-date, outperforming the S&P 500's gain of 8.4% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.06 on revenues of $24.48 million, while for the current fiscal year, the estimate is $1.36 on revenues of $94.1 million [7] - The estimate revisions trend for Zevra Therapeutics was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Drugs industry, to which Zevra Therapeutics belongs, is currently ranked in the top 35% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Viewpoint - Co-Diagnostics, Inc. reported a quarterly loss of $0.23 per share, which was better than the Zacks Consensus Estimate of a loss of $0.25, indicating an earnings surprise of +8.00% [1] Financial Performance - The company posted revenues of $0.16 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 45.67%, and a significant decline from $2.66 million in the same quarter last year [2] - Over the last four quarters, Co-Diagnostics has surpassed consensus EPS estimates three times [2] - The current consensus EPS estimate for the upcoming quarter is -$0.16 on revenues of $0.3 million, and for the current fiscal year, it is -$0.68 on revenues of $0.95 million [7] Stock Performance - Co-Diagnostics shares have declined approximately 64.9% since the beginning of the year, contrasting with a 10% gain in the S&P 500 [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it is expected to perform in line with the market in the near future [6] Industry Outlook - The Medical Services industry, to which Co-Diagnostics belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact investor sentiment [5]

Core Viewpoint - Natural Gas Services (NGS) shares have increased by 6.8% recently, with analysts suggesting a potential upside of 41.7% based on a mean price target of $36.25 [1][11]. Price Targets - The average price target for NGS ranges from a low of $32.00 to a high of $45.00, with a standard deviation of $5.97, indicating variability among analysts [2]. - The lowest estimate suggests a 25.1% increase, while the highest points to a 75.9% upside [2]. Analyst Sentiment - There is strong agreement among analysts regarding NGS's ability to report better earnings, which supports the expectation of an upside [4][11]. - Over the past 30 days, the Zacks Consensus Estimate for the current year has risen by 5.7%, with no negative revisions [12]. Zacks Rank - NGS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]. Conclusion on Price Movement - While consensus price targets may not be entirely reliable, the direction indicated by these targets appears to be a useful guide for potential price movement [14].

Group 1 - INPLAY OIL CP reported quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.26 per share, representing an earnings surprise of -80.77% [1] - The company posted revenues of $66.23 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 3.11%, compared to year-ago revenues of $30.3 million [2] - The stock has added about 9% since the beginning of the year, while the S&P 500 has gained 10% [3] Group 2 - The earnings outlook for INPLAY OIL CP is mixed, with the current consensus EPS estimate for the coming quarter at $0.17 on $64.01 million in revenues, and $0.56 on $220.02 million in revenues for the current fiscal year [7] - The Zacks Industry Rank for Oil and Gas - Exploration and Production - Canadian is currently in the top 25% of over 250 Zacks industries, indicating a favorable industry outlook [8]

Company Performance - Oncobiologics reported a quarterly loss of $0.44 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.42, but an improvement from a loss of $0.83 per share a year ago, indicating a year-over-year improvement in losses [1] - The company posted revenues of $1.51 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 40.98%, compared to zero revenues a year ago [2] - Over the last four quarters, Oncobiologics has surpassed consensus EPS estimates two times [2] Stock Performance - Oncobiologics shares have increased by approximately 12.7% since the beginning of the year, outperforming the S&P 500's gain of 10% [3] - The current Zacks Rank for Oncobiologics is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the coming quarter is -$0.33 on revenues of $5.78 million, and for the current fiscal year, it is -$1.89 on revenues of $6.42 million [7] - The outlook for the Medical - Biomedical and Genetics industry, in which Oncobiologics operates, is currently in the bottom 41% of over 250 Zacks industries, suggesting potential challenges ahead [8]

Group 1 - VYNE Therapeutics Inc. reported a quarterly loss of $0.13 per share, better than the Zacks Consensus Estimate of a loss of $0.23, representing an earnings surprise of +43.48% [1] - The company posted revenues of $0.07 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 31%, and a decline from $0.2 million in the same quarter last year [2] - VYNE Therapeutics shares have decreased by approximately 89.6% since the beginning of the year, contrasting with the S&P 500's gain of 10% [3] Group 2 - The current consensus EPS estimate for the upcoming quarter is -$0.25 on revenues of $0.15 million, and for the current fiscal year, it is -$0.94 on revenues of $0.6 million [7] - The Medical - Drugs industry, to which VYNE Therapeutics belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]